Janux Therapeutics, Inc.
For the period ended Sep 30, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 5, 2026
JANX$12.04-5.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Condensed Statements of Operations and Comprehensive Loss
(in thousands, except share and per share data)
| Three Months EndedSeptember 30, | Nine Months EndedSeptember 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Collaboration revenue | $9,289 | $10,000 | $23,289 | $10,000 |
| Operating expenses: | ||||
| Research and development | 30,565 | 34,629 | 88,372 | 94,348 |
| General and administrative | 9,982 | 10,622 | 32,078 | 30,918 |
| Total operating expenses | 40,547 | 45,251 | 120,450 | 125,266 |
| Loss from operations | (31,258) | (35,251) | (97,161) | (115,266) |
| Other income: | ||||
| Interest income | 9,688 | 10,938 | 29,258 | 33,587 |
| Total other income | 9,688 | 10,938 | 29,258 | 33,587 |
| Net loss | $(21,570) | $(24,313) | $(67,903) | $(81,679) |
| Other comprehensive gain (loss): | ||||
| Unrealized gain (loss) on available-for-sale securities, net | (4,189) | 815 | (10,810) | 2,399 |
| Comprehensive loss | $(25,759) | $(23,498) | $(78,713) | $(79,280) |
| Net loss per common share, basic and diluted | $(0.34) | $(0.39) | $(1.08) | $(1.32) |
| Weighted-average shares of common stock outstanding, basic and diluted | 63,089,950 | 62,023,685 | 62,899,208 | 61,906,789 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.